Prostate Cancer  
Measure #2: Initial Evaluation, New Diagnoses

This measure may be used as a Quality Improvement measure only.

<table>
<thead>
<tr>
<th>Clinical Performance Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Numerator:</strong> Patients with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score</td>
</tr>
<tr>
<td><strong>Denominator:</strong> All patients, regardless of age, with a new diagnosis of prostate cancer</td>
</tr>
<tr>
<td><strong>Denominator Exceptions:</strong> Documentation of medical reason(s) for not evaluating prostate-specific antigen (PSA), OR primary tumor (T) stage, OR Gleason score (eg, salvage therapy)</td>
</tr>
<tr>
<td>Documentation of patient reason(s) for not evaluating prostate-specific antigen (PSA), OR primary tumor (T) stage, OR Gleason score</td>
</tr>
<tr>
<td><strong>Measure:</strong> Percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score</td>
</tr>
</tbody>
</table>

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure:

- Tumor characteristics, including PSA level and changes such as velocity and doubling time, Gleason score, and tumor stage, are predictive of cancer outcomes. Using PSA, Gleason score, and tumor stage, risk strata have been defined that are significantly associated with PSA recurrence and cancer specific mortality. *(AUA², 2007)*

- The combination of Gleason score, PSA level, and stage can effectively stratify patients into categories associated with different probabilities of achieving a cure. In addition to considering the probability of cure, the choice of initial treatment is highly influenced by estimated life expectancy, comorbidities, potential therapy side effects, and patient preference. *(Category 2A) (NCCN¹, 2005)*

**Rationale for the measure:**

The initial assessment of all prostate cancer patients should include the three evaluations required in this measure. This measure differs from Measure #1 in that the denominator population is limited to patients with a new diagnosis of prostate cancer. This information is not currently available from physician billing codes and presents a documentation and data collection burden; the measure is therefore designated for only quality improvement use at this time.

Data elements required for the measure can be captured and the measure is actionable by the physician.
A. Administrative claims data

Administrative claims data collection requires users to identify the eligible population (denominator) and numerator using codes recorded on claims or billing forms (electronic or paper). Users report a rate based on all patients in a given practice for whom data are available and who meet the eligible population/denominator criteria.

**Denominator (Eligible Population):** All patients with a new diagnosis of prostate cancer

**ICD-9-CM diagnosis codes for prostate cancer [reportable through 9/30/2015]:** 185 (new diagnosis)

**OR**

**ICD-10-CM diagnosis codes for prostate cancer [reportable beginning 10/01/2015]:** C61 (new diagnosis)

**AND**

**CPT Codes:** 99201, 99202, 99203, 99204, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245

**Numerator:** Patients with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score

Report the CPT Category II code designated for this numerator:

**3268F:** Prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score documented prior to initiation of treatment

**Denominator Exceptions:**

Documentation of medical reason(s) for not evaluating prostate-specific antigen (PSA), OR primary tumor (T) stage, OR Gleason score (eg, salvage therapy)

- **Append modifier to CPT Category II code : 3268F-1P**

Documentation of patient reason(s) for not evaluating prostate-specific antigen (PSA), OR primary tumor (T) stage, OR Gleason score

- **Append modifier to CPT Category II code : 3268F-2P**